Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

We screened TP53 mutations in 168 MDS patients who were treated with HMA and evaluated predictive and prognostic value of TP53 mutations. Overall response to HMA was not different based on TP53 mutation status (45% vs. 32% in TP53-mutated and wild type [WT], respectively, P = 0.13). However, respons...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Takahashi, Koichi, Patel, Keyur, Bueso-Ramos, Carlos, Zhang, Jianhua, Gumbs, Curtis, Jabbour, Elias, Kadia, Tapan, Andreff, Michael, Konopleva, Marina, DiNardo, Courtney, Daver, Naval, Cortes, Jorge, Estrov, Zeev, Futreal, Andrew, Kantarjian, Hagop, Garcia-Manero, Guillermo
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924706/
https://ncbi.nlm.nih.gov/pubmed/26871476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7290
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars